Merck Stock Drops 081% as Trading Volume Plummets to 72nd Position Despite AI Innovation

On June 25, 2025, Merck (MRK) experienced a significant decline, with its trading volume reaching $10.16 billion, marking a 20.49% decrease from the previous day. This placed Merck at the 72nd position in terms of trading volume for the day. The stock price of Merck dropped by 0.81%.

Merck has introduced a new internal generative AI-powered platform designed to streamline the clinical trial process. This platform leverages advanced data engineering and large language models (LLMs) to expedite the development of clinical study reports, thereby accelerating the delivery of medicines to patients. The new system has successfully reduced the time required to produce a fully human-reviewed first draft of a clinical study report from an average of 180 hours to just 80 hours. Additionally, it has improved the quality of these drafts by reducing errors by 50% in categories such as data, messaging, citations, terminology, and typography.

This innovative platform is part of Merck's broader initiative to enhance its technology architecture and business capabilities. The company has collaborated with McKinsey & Company and its AI arm, QuantumBlack, to develop solutions that leverage LLMs. These solutions have been successfully implemented in multiple studies, demonstrating significant improvements in efficiency and accuracy. The platform integrates advanced table pre-processing with generative AI authoring, delivering high-quality first drafts in as little as five minutes. This integration has required Merck to revamp its operations and train teams in prompt engineering, data pipelines, and other critical skills.

Merck is currently in the process of scaling this platform across its late-phase pipeline, with the goal of completing this by the end of the year. The company aims to use data science, AI, and machine learning to overcome bottlenecks in drug discovery, research, and development. Merck's commitment to innovation and efficiency is evident in its efforts to bring lifesaving medicines to patients faster, leveraging the power of leading-edge science to save and improve lives around the world.